Our proprietary platform targets, predicts and unlocks novel Bioactive Peptides from food sources.
These deliver highly specific, efficient and
life-changing health solutions.

70+ core predictors
1 million+ novel peptides discovered in 2019
Millions of peptides
per health area
Billions of target
60%+ accuracy rate
Millions of public
experimental observations
10,000+ assay results

Nuritas is using nature as a library, and AI as the method to identify those peptides that may have an impact in a specific disease area.

Remarkably, a single apple offers more molecular data than all social media put together! On average, plants and other organic matter contain more than 30 billion peptides.

The Nuritas artificial intelligence platform provides the largest peptide database in the world for our drug hunters to explore, and offers the potential to expand and enhance the scope, efficacy and accuracy of discovery in the biopharmaceutical industry.

Using our drug discovery platform and the insights from our successful commercialization of clinically validated peptides in the Consumer market, we can identify peptide sequences, combining them to address structural priorities and characteristics of efficacy, cell penetration, and stability. We can also chemically optimize them on computers, and in vitro and in vivo in the lab to improve those traits.

The Opportunity

AI is now much better than humans in recognizing images. We are using the same type of image-recognition technology to identify peptides. With an infinite number of peptides, the process of peptide discovery is extraordinarily challenging to humans, but machine learning, both supervised and unsupervised, allows us to significantly improve the timing and accuracy of drug discovery.

Traditional drug screening accuracy rates offer a remarkably low success rate, often less than 0.001%.

Using our AI platform, we have demonstrated an extraordinary rate of accuracy:

> 63% in discovering single new, completely novel peptide ligands for a known drug target
> 45% in cocktails of peptides for a multi-targeted disease state
In complex diseases such as muscular dystrophy, we avoid facing the same failures as others have experienced by identifying more than one target to shift the signaling within the cell.
> 60% in discovering a peptide-based, systems biology solution to diseases without known drug targets
This approach offers the dual benefit of discovering a peptide that provides a desired therapeutic solution while at the same time identifying a new drug target for the disease.


Our Solution

The Nuritas Peptide Finder

Developed and continually updated and curated over the last five years, our proprietary software can access and integrate three distinct inputs from our peptide library:
A manually curated and formatted peptide database containing all relevant literature, patents, and information from both public and paid website domains
The data are structured in such a way that our AI system can access and continuously learn. This undertaking has been an enormous task, and requires constant attention and management. Because every paper is written differently, reproducibility is poor, and experiments are not conducted in any consistent manner, the curation allows us to clean the data and shape the content for machine learning.

A collection of natural plant, animal and marine samples from around the world
We analyze them using Mass Spectrometry and input the resulting data into the system. This process has given us what is arguably the largest peptide database in the world.

An extensive data library of experimental data peptide testing
Since our founding in 2014, we have tested pure peptides and mixes of peptides on different cell types. We have collected the data, looked at the output in terms of gene expression, biomarkers and other parameters, and we have entered all of the resulting information into our proprietary software system. These inputs allow the system to discover solutions for a given target or a given indication. All data collected, internal or external with a CRO, are translated back into the system and integrated with the life of the peptide data set.

Most of the Nuritas proprietary software databases are integrated, working both individually and collectively, and sporting their own identifying names such as Pantry, Amplify, and Edge. The network of data access allows our team of Ph.D. scientists and engineers to collaborate around queries to the machine learning capability to generate hypotheses for our own product pipeline, often arriving at a biologically-validated, patentable molecule in less than 12 months.

As we advance peptides through our pipeline, we utilize the platform on an iterative basis to continually improve a peptide candidate’s profile, selectivity, and other key characteristics, eventually arriving at an optimized lead candidate that will meet a target clinical and commercial profile. This process not only ensures the lead candidate meets the target profile, but also expands our knowledge in the pathway to provide multiple opportunities to address compensatory pathways and other conformational changes resulting from systems biology that may require a multi-targeted, multi-drug approach to treat the disease condition.


A huge and growing library of patented Bioactive Peptides with extraordinary potential.

Our library of plant and animal derived Bioactive Peptides have gone through hundreds of millions of years of selective evolution to become the most potent repairers, healers and protectors.